Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified ...

TD Cowen began coverage of Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy rating, citing the company's strong position in ...

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Monday. A ...

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) is expected to issue its quarterly earnings data on Thursday, February 20th. Analysts expect the company to announce earnings of ($0.82) per share and ...

Congenital adrenal hyperplasia (CAH) is a monogenic autosomal recessive disorder and more than 150 mutations of the CYP21A2 gene have been already reported and based on the degree of the enzymatic ...

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) stock has reached a 52-week low, trading at $35.47, with InvestingPro technical indicators showing oversold conditions. The stock has declined sharply, ...

clinical or biochemical hyperandrogenism and the exclusion of other known disorders, such as late-onset congenital adrenal hyperplasia and Cushing's syndrome. The more recent 2003 Rotterdam ...

Other symptoms of PCOS include: Nonclassic congenital adrenal hyperplasia (NCCAH) is a genetic disorder. The late-onset form has similar symptoms to PCOS. It is due to a missing enzyme responsible for ...